InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

1 October, 2018

InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting.

InteRNA OTS Data Announcement

Please click here to read InteRNA Post er #63 showing the data

Please click here to read InteRNA Poster #114 showing the data

EVENTS

13 January 2020 - 15 January 2020

Biotech Showcase™, San Francisco, USA

04 February 2020 - 05 February 2020

LSX World Congress, London, UK

19 February 2020 - 20 February 2020

11th Annual RNA Therapeutics Conference, London, UK

NEWS

31 October, 2019

InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting

31 October, 2019

InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

15 May, 2019

InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy

25 March, 2019

InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

1 October, 2018

InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

1-5 6-10 11-15 16-20 21-25 26-30